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Is parathyroid hormone 
measurement useful for the 
diagnosis of renal bone disease?
TB Drüeke1
The non-invasive diagnosis of bone turnover in patients with 
chronic kidney disease (CKD) remains difficult compared with bone 
histomorphometry as the gold standard. Most clinicians rely on 
surrogate markers, mainly serum parathyroid hormone and total alkaline 
phosphatases, in association with serum calcium and phosphorus. 
Although very high serum PTH levels generally allow the diagnosis of 
high bone turnover, slight elevations, normal, or low values cannot allow a 
reliable distinction between normal or low turnover. 
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I n  t h e  p a s t  d e c a d e s ,  c l i n i c a l 
nephrologists have become used to con-
sidering so-called ‘intact’ parathyroid 
hormone (PTH) a reliable surrogate 
marker for bone turnover in patients 
with chronic kidney disease and the 
associated mineral and bone disorder 
(CKD-MBD). Although many other 
circulating markers of bone turnover 
have been examined and proposed for 
diagnostic and therapeutic purposes in 
patients with CKD,1 none of them has 
gained widespread acceptance in clini-
cal routine.
The use of PTH as ﬁrst choice for the 
characterization of normal versus path-
ologic bone in CKD was reinforced by 
the Kidney Disease Outcomes Quality 
Initiative (K/DOQI) guidelines on bone 
metabolism and disease in 2003,2 which 
set circulating ‘intact’ PTH values for 
chronic dialysis patients with suppos-
edly normal bone turnover at values 
between 150 and 300 pg/ml, that is, 
approximately two to three times higher 
than the upper limit of normal using 
Nichols Allegro immunoradiometric 
assay for ‘intact’ PTH (N-IRMA, no 
longer available). For CKD patients not 
yet on dialysis, the corresponding PTH 
target was arbitrarily set to somewhat 
lower values, in the absence of reliable 
data in the literature. This PTH guide-
line was issued despite voices of dissent 
questioning the validity of predicting 
bone turnover on the basis of these 
ranges of serum ‘intact’ PTH;3 argu-
ing that the serum PTH range reﬂect-
ing normal bone turnover needed to 
be lower with another assay (B-IRMA) 
that measured not PTH fragments like 
the Nichols assay, but exclusively the 
whole PTH molecule;4 and arguing that 
aluminum overload should be taken 
into account in the interpretation of 
the predictive value of any serum PTH 
measurement.5 Other discordant ﬁnd-
ings were made in children and adoles-
cents on long-term dialysis treatment. 
Intermittent calcitriol therapy given to 
these patients resulted, at least in some 
of them, in normalization of bone for-
mation despite persistently elevated 
serum ‘intact’ PTH levels. Only in those 
patients who developed adynamic bone 
disease did the serum PTH decrease.6
The issue of the relationship between 
circulating PTH and bone turnover has 
gained an additional degree of complexity 
since the disappearance from the market 
of Nichols N-IRMA and the introduction 
of numerous other, presently available 
PTH detection assays. Most of them are 
of the so-called second generation, meas-
uring ‘intact’ PTH, that is, both the whole 
PTH molecule and PTH fragments, with 
limited comparability from one assay to 
another.7 Others measure ‘whole’ PTH 
(also called ‘bio-intact’ PTH) alone. None 
of the new assays has been validated with 
respect to bone biopsy ﬁndings. Hope-
fully, such validations will be reported in 
the near future.
Barreto et al.8 (this issue) provide a 
breath of fresh air to the above voices 
of dissent. They decided to assess, in a 
cohort of patients undergoing intermit-
tent hemodialysis in São Paulo, Brazil, 
to what extent the ‘intact’ PTH range of 
150–300 pg/ml reﬂected normal bone 
turnover. They followed 97 patients for 
one year. They obtained a bone biopsy 
in each of them at baseline and a repeat 
biopsy in 64 of them 12 months later. 
The results obtained were incompat-
ible with the K/DOQI recommended 
‘normal’ ‘intact’ PTH range for CKD 
stage 5D patients. Two-thirds of those 
subjects whose baseline PTH was in that 
range had low-turnover bone disease on 
the basis of bone histomorphometry, 
and one in four had high-turnover bone 
disease. After one year of follow-up, 
the discrepancy between ‘intact’ PTH 
and bone biopsy ﬁndings was similar. 
Moreover, normalization of bone turno-
ver was diﬃcult to achieve even in those 
patients whose serum ‘intact’ PTH val-
ues could be maintained in the recom-
mended K/DOQI range.
The question then arises of why Bar-
reto et al.8 failed to conﬁrm the K/DOQI 
deﬁnitions of the optimal serum ‘intact’ 
PTH range for CKD stage 5D patients. 
There may be several reasons.
First of all, one could speculate that 
the Brazilian dialysis patients were dif-
ferent from those in Europe or North 
America. However, Ferreira et al. 
recently reported a similar dissocia-
tion between bone histomorphometry 
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Figure 1 | PTH and bone turnover in chronic kidney disease.
ﬁndings and serum ‘intact’ PTH in a 
chronic hemodialysis patient cohort 
from Portugal.9 They performed a rand-
omized open-label study comparing the 
eﬀects on bone histology of sevelamer 
hydrochloride with those of calcium 
carbonate at baseline, and again after 
one year of follow-up. Like Barreto et 
al.,8 they found a high prevalence of 
low-turnover bone disease despite well-
controlled serum calcium, phosphorus, 
and ‘intact’ PTH levels in the majority 
of the patients, according to K/DOQI 
criteria, both at baseline and after one 
year of follow-up, with serum ’intact’ 
PTH levels mostly in the lower half of 
the recommended range in the calcium 
group and in the upper half or slightly 
above in the sevelamer group.
Second, the patients in the study by 
Barreto et al.8 had a relatively high 
prevalence of aluminum overload on 
the basis of bone histology analysis, 
compared with the patients of many 
other such studies. This should have 
changed the relationship between 
serum PTH and bone histology find-
ings, as aluminum intoxication could 
create a state of skeletal resistance to 
PTH, according to Fournier et al.4 Bar-
reto et al.8 did not find a correlation 
of low-turnover bone disease with the 
presence of positive aluminum stain-
ing in their patient cohort, in contrast 
to obvious correlations with the tra-
ditional risk factors age and diabetes. 
Absence of correlation, however, does 
not necessarily imply absence of causa-
tion. It is noteworthy that 60% of their 
patients with low-turnover bone disease 
had strongly positive bone aluminum 
staining (aluminum bone surface/total 
bone surface >25%), compared with 
only 30% of their patients with high-
turnover bone disease. Ferreira et al. 
observed the above-mentioned discrep-
ancy between ‘intact’ PTH and bone 
histology in the absence of stainable 
bone aluminum greater than 20% at 
study start, but they did not report the 
proportion of patients with zero alumi-
num staining in their study.9
Third, Barreto et al.8 used Immulite 
assay to measure ‘intact’ PTH, in con-
trast to previous studies, which most 
often used Nichols N-IRMA. According 
to Souberbielle et al.,7 ‘intact’ PTH 
values obtained with Immulite assay 
present a positive median bias of 38% 
compared with N-IRMA. By a simple 
rule of 3, this would mean that, with 
the Immulite assay, both the lower and 
the upper serum PTH limits should 
have been set at somewhat higher 
values, roughly at a range of 210–410 
pg/ml, although it is diﬃcult to adjust 
values obtained with one assay to those 
obtained with another assay. Barreto 
et al.8 say that they nevertheless made 
such an adjustment; this should have 
slightly reduced the number of patients 
with low-turnover bone disease who 
had ‘intact’ PTH levels above the upper 
limit of this adapted range, although a 
substantial number among them would 
still have been erroneously misclassiﬁed 
as having high-turnover bone disease 
on the basis of Immulite PTH measure-
ment alone.
Fourth, Barreto et al.8 used reference 
ranges for dynamic parameters of bone 
histomorphometry that were estab-
lished in a control population of North 
America, with possibly a higher degree 
of vitamin D insuﬃciency and higher 
serum PTH levels than in the general 
population of the São Paulo area in 
Brazil. If so, this would have shifted the 
lower range of normal bone turnover 
toward somewhat higher levels than it 
would have been with local controls. 
This in turn could have led to a certain 
overestimation of the prevalence of low 
bone turnover in the dialysis patients 
studied by Barreto et al.8
Finally, a number of actors other 
than PTH play a role in the regulation 
of bone formation and resorption. We 
already have mentioned age and diabe-
tes. One has to add further the influ-
ence of numerous endogenous and 
exogenous factors. Among the former, 
several hormones, growth factors, and 
cytokines have been shown to modulate 
bone turnover.10 Among the latter, the 
administration of excessive amounts of 
aluminum-containing phosphate bind-
ers, calcium-containing compounds, 
and/or active vitamin D derivatives 
has long been known to reduce bone 
turnover.
Where do these recent studies on 
the complex relations between serum 
‘intact’ PTH and bone histology lead 
us? The widely accepted association 
between circulating PTH values and the 
type of renal osteodystrophy will have 
to be redeﬁned, as suggested in Figure 
1, with probable diﬀerences from one 
PTH assay to another. In the future, 
reliable bone-derived markers of bone 
formation and resorption probably 
will replace ‘intact’ PTH as the main 
surrogate marker for bone turnover 
in patients with CKD. The claim that 
third-generation ‘whole’ (or ‘bio-intact’) 
PTH assays may have a higher predic-
tive value than ‘intact’ PTH assays for 
the diﬀerential diagnosis between low- 
and high-turnover bone disease states 
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needs to be conﬁrmed by future direct 
confrontations with bone biopsy ﬁnd-
ings. Ideally, invasive methods such 
as bone biopsy should be replaced by 
a combination of biochemical mark-
ers and highly performing imaging 
techniques for an optimal assessment 
of bone structure and function, the 
prediction of fractures, and adequate 
treatment and prevention.
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